SCHEMBL3528652

SCHEMBL3528652

COC(=O)CCCc1cc2cc(Cl)ccc2n1S(=O)(=O)c1cccc(Cl)c1Cl

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PPARG P37231 19/20 0.60
PPARA Q07869 13/20 0.60
PPARD Q03181 13/20 0.58
ACLY P53396 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522836 0.94 PPARG (0.55) PPARGPPARAPPARDACLY
SCHEMBL3525915 0.88 PPARG (0.76) PPARGPPARAPPARDACLY
SCHEMBL3526424 0.88 PPARG (0.79) PPARGPPARAPPARD
SCHEMBL3525789 0.84 PPARG (0.58) PPARGPPARAPPARD
SCHEMBL3524660 0.84 PPARG (0.78) PPARGPPARAPPARD
SCHEMBL3527808 0.84 PPARG (0.71) PPARGPPARAPPARDACLY
SCHEMBL3525926 0.83 PPARG (0.56) PPARGPPARAPPARD
SCHEMBL3529286 0.82 PPARG (0.57) PPARGPPARAPPARD
SCHEMBL3526127 0.82 PPARG (0.84) PPARGPPARAPPARD
SCHEMBL3523615 0.82 PPARG (0.55) PPARGPPARAPPARDACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP PPARG 1018/4885PPARA 847/4885PPARD 677/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.